Abstract
Mitochondrial metabolism is a highly orchestrated phenomenon in which many enzyme systems cooperate in a variety of pathways to dictate cellular fate. As well as its vital role in cellular energy metabolism (ATP production), mitochondria are powerful organelles that regulate reactive oxygen species production, NAD+/NADH ratio and programmed cell death. In addition, mitochondrial abnormalities have been well-recognized to contribute to degenerative diseases, like Parkinsons disease (PD). Particularly a deficiency in the mitochondrial respiratory chain complex I and cristae disruption have been consistently described in PD. Moreover, the products of PD-familial genes, including α-synuclein, Parkin, PINK1, DJ-1, LRRK2 and HTR2A, were shown to localize to the mitochondria under certain conditions. It seems that PD has a mitochondrial component so events that would modulate normal mitochondrial functions may compromise neuronal survival. However, it remains an open question whether alterations of these pathways lead to different aspects of PD or whether they converge at a point that is the common denominator of PD pathogenesis. In this review we will focus on mitochondrial metabolic control and its implications on sirtuins activation, microtubule dynamics and the autophagic-lysosomal pathway. We will address mitochondrial metabolism modulation as a new promising therapeutic tool for PD.
Keywords: Mitochondria, Parkinson's disease, autophagy, sirtuins, microtubules, mitochondrial metabolism, therapeutic targets, metabolic control
CNS & Neurological Disorders - Drug Targets
Title: Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinsons Disease
Volume: 9 Issue: 1
Author(s): D. M. Arduino, A. R. Esteves, C. R. Oliveira and S. M. Cardoso
Affiliation:
Keywords: Mitochondria, Parkinson's disease, autophagy, sirtuins, microtubules, mitochondrial metabolism, therapeutic targets, metabolic control
Abstract: Mitochondrial metabolism is a highly orchestrated phenomenon in which many enzyme systems cooperate in a variety of pathways to dictate cellular fate. As well as its vital role in cellular energy metabolism (ATP production), mitochondria are powerful organelles that regulate reactive oxygen species production, NAD+/NADH ratio and programmed cell death. In addition, mitochondrial abnormalities have been well-recognized to contribute to degenerative diseases, like Parkinsons disease (PD). Particularly a deficiency in the mitochondrial respiratory chain complex I and cristae disruption have been consistently described in PD. Moreover, the products of PD-familial genes, including α-synuclein, Parkin, PINK1, DJ-1, LRRK2 and HTR2A, were shown to localize to the mitochondria under certain conditions. It seems that PD has a mitochondrial component so events that would modulate normal mitochondrial functions may compromise neuronal survival. However, it remains an open question whether alterations of these pathways lead to different aspects of PD or whether they converge at a point that is the common denominator of PD pathogenesis. In this review we will focus on mitochondrial metabolic control and its implications on sirtuins activation, microtubule dynamics and the autophagic-lysosomal pathway. We will address mitochondrial metabolism modulation as a new promising therapeutic tool for PD.
Export Options
About this article
Cite this article as:
Arduino M. D., Esteves R. A., Oliveira R. C. and Cardoso M. S., Mitochondrial Metabolism Modulation: A New Therapeutic Approach for Parkinsons Disease, CNS & Neurological Disorders - Drug Targets 2010; 9 (1) . https://dx.doi.org/10.2174/187152710790966687
DOI https://dx.doi.org/10.2174/187152710790966687 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Phytochemicals: Potential in Management of Climacteric Neurobiology
Current Pharmaceutical Design Targeting Extracellular Matrix Proteolysis for Hemorrhagic Complications of tPA Stroke Therapy
CNS & Neurological Disorders - Drug Targets Endoplasmic Reticulum Stress and Bipolar Disorder - Almost Forgotten Therapeutic Drug Targets in the Unfolded Protein Response Pathway Revisited
CNS & Neurological Disorders - Drug Targets Disruption of Zinc Neuromodulation by Aß Oligomers : Therapeutic Implications
Current Pharmaceutical Design A Novel Multi-Target Drug Screening Strategy Directed Against Key Proteins of DAPk Family
Combinatorial Chemistry & High Throughput Screening Molecular Mechanisms of Liver Cancer
Anti-Cancer Agents in Medicinal Chemistry Metabotropic Glutamate Receptors and Interacting Proteins in Epileptogenesis
Current Neuropharmacology The Use of Dexmedetomidine in Anesthesia and Intensive Care: A Review
Current Pharmaceutical Design Mechanisms Underlying the Cardiovascular Effects of COX-Inhibition: Benefits and Risks
Current Pharmaceutical Design Mitochondria-Targeted Antioxidant Peptides
Current Pharmaceutical Design Gut-Brain Axis in Gastric Mucosal Damage and Protection
Current Neuropharmacology Pitfalls and Solutions for the Validation of Novel Drugs in Animal Models of Disease
Current Immunology Reviews (Discontinued) “PARG Inhibitors’ Success: A Long Way to Go!”
Current Enzyme Inhibition High-Density Lipoprotein at the Interface of Type 2 Diabetes Mellitus And Cardiovascular Disorders
Current Pharmaceutical Design Endogenous Events Modulating Myogenic Regulation of Cerebrovascular Function
Current Vascular Pharmacology AMPK as a New Attractive Therapeutic Target for Disease Prevention: The Role of Dietary Compounds AMPK and Disease Prevention
Current Drug Targets Protein-Energy Malnutrition Alters Hippocampal Plasticity-Associated Protein Expression following Global Ischemia in the Gerbil
Current Neurovascular Research Neuroprotection by Natural Polyphenols: Molecular Mechanisms
Central Nervous System Agents in Medicinal Chemistry 5-Aminoisoquinolin-1-one (5-AIQ), a Water-Soluble Inhibitor of the Poly(ADP-Ribose)Polymerases (PARPs)
Current Medicinal Chemistry Targeting Resveratrol to Mitochondria for Cardiovascular Diseases
Recent Patents on Cardiovascular Drug Discovery